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A
 
BSTRACT
 
Asthma is regarded as an inflammatory disorder of the
conducting airways characterized by a mast cell, eosin-
ophil and T lymphocyte inflammatory response that is
responsive to anti-inflammatory therapy, such as corti-
costeroids. In more severe and chronic disease, corti-
costeroids become less effective. As in other chronic
inflammatory diseases, the tissue in which the cellular
and mediator processes occur plays a major role in
maintaining the response and creating a basis for
disease persistence. Herein, we describe evidence that
the airway epithelium interacting with the underlying
mesenchymal cells recapitulates branching morpho-
genesis, as observed in the developing lung, to create
airway wall remodeling. The reciprocal signaling
between the susceptible epithelium and responsive
mesenchyme (epithelial mesenchymal trophic unit)
offers a new paradigm for asthma and creates new
opportunities for developing therapeutics based on
reversing the ‘chronic wound’ phenotype of asthmatic
airways. 
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I
 
NTRODUCTION
 
A recent National Institutes of Health (NIH) workshop
and a European Respiratory Society (ERS) Task Force
both concluded that more work is needed to understand
mechanisms of severe and chronic asthma.
 
1,2
 
 This disease
significantly affects quality of life and is an important
socioeconomic burden. Recognizing that, in isolation,
T-helper 2 (Th-2)-mediated inflammation is insufficient
to cause asthma, we suggest that the asthmatic state
results from a combination of the increased susceptibility
of the bronchial epithelium to injury and prolonged
tissue repair involving an imbalance in responses to
heregulin receptor ligands, such as epithelium growth
factor (EGF), tyrosine kinase receptor ligands, such as
the transforming growth factor (TGF)-
 
β
 
 and Th-2 T cell
cytokines. These alter cell–cell communication between
the epithelium and the underlying attenuated fibroblast
sheath, causing activation of the epithelial mesenchymal
trophic unit (EMTU), thereby propagating and amplifying
remodeling of the airways and sustaining chronic
inflammation, which are linked to both asthma chro-
nicity and the reduced efficacy of corticosteroids.
 
A
 
STHMA
 
: A 
 
DYNAMIC
 
 
 
DISORDER
 
 
 
OF
 
 
 
INFLAMMATION
 
 
 
AND
 
 
 
REMODELING
 
Asthma is an inflammatory disorder of the airways
involving T cells, mast cells and eosinophils character-
istic of a Th-2 response. However, inflammation alone
does not explain many of the features of this chronic and
relapsing disease. While atopy is an important risk factor
for asthma, in the general population it only accounts
for 40% of the attributable risk of having this disease.
 
3
 
Eosinophils have been assumed to play a central role in
disease pathogenesis; however, studies with an anti-
interleukin (IL)-5 blocking monoclonal antibody
 
4
 
 and
recombinant human IL-12
 
5
 
 have failed to reveal effi-
cacy, despite markedly reducing circulating and airway
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eosinophil numbers. Thus, while being associated with
asthma, atopy and airway eosinophilia would not seem
to be critical requirements for disease expression.
Genetic studies have also demonstrated that atopy and
bronchial hyperresponsiveness (BHR) have different pat-
terns of inheritance.
 
6
 
 These findings imply that locally
operating factors play an important role in predisposing
individuals to asthma and provide an explanation for
epidemiologic evidence that identifies pollutant expo-
sure,
 
7
 
 diet
 
8
 
 and respiratory virus infection,
 
9
 
 which all
increase oxidant stress in the airways, as important
disease risk factors.
Morphometry has revealed that thickening of asth-
matic airways accounts for a large component of BHR
and excessive airway narrowing observed in established
disease. In moderate–severe disease, these structural
changes, along with BHR, are poorly responsive to corti-
costeroids.
 
10
 
 This failure of corticosteroids is reflected in
the findings of our recent European Network For the
Understanding Of Severe Asthma (ENFUMOSA) study,
which has revealed that these patients exhibit a greatly
impaired quality of life,
 
11
 
 a component of fixed airflow
obstruction and have clear evidence of airway wall
remodeling.
 
12
 
 In such patients, we have found evidence
of persistent matrix turnover with higher levels of cleaved
tenascin C, matrix metalloproteinase-2 and collagen VI,
indicating active tissue remodeling.
 
13
 
 Airway remode-
ling in adult asthma also provides an explanation for
the accelerated decline in lung function observed over
time.
 
13
 
 The recent Childhood Asthma Management
Program (CAMP) study in 5–11-year-old children has
shown that the initial beneficial effect of an inhaled
corticosteroid on the post-bronchodilator improvement
in airway function observed during the first year of treat-
ment was lost over the following 3 years.
 
14
 
 This is best
explained by airway remodeling that is insensitive to
corticosteroids. A recent biopsy study has identified
tissue remodeling as an early and consistent component
of childhood asthma with fibroblast proliferation and
collagen deposition in the subepithelial lamina reticula-
ris being of greater diagnostic significance than tissue
eosinophilia.
 
15
 
 Although remodeling has been con-
sidered to be secondary to long-standing inflammation,
biopsy studies in young children have shown tissue
restructuring up to 4 years before the onset of symp-
toms,
 
16
 
 indicating processes that begin early in the
development of asthma and occur in parallel with, or
may be obligatory for, the establishment of persistent
inflammation.
 
E
 
PITHELIAL
 
 
 
SUSCEPTIBILITY
 
 
 
TO
 
 
 
INJURY
 
 
 
AND
 
 
 
THE
 
 
 
REPAIR
 
 
 
PHENOTYPE
 
 
 
IN
 
 
 
ASTHMA
 
The normal bronchial epithelium is a stratified structure
consisting of a columnar layer supported by basal cells
to serve as a physical and chemical barrier to the
external environment. In asthma, the epithelium shows
evidence of activation linked to structural damage and
goblet cell metaplasia. Epithelial stress is seen in the
form of widespread activation of the transcription factors
nuclear factor-
 
κ
 
B,
 
17,18
 
 activator proteins (e.g. AP-1)
 
19
 
and signal transducer and activation of transcription
(STAT)-1,
 
20
 
 and by the increased expression of heat
shock proteins
 
21
 
 and the cyclin-dependent kinase inhibi-
tor p21
 
waf
 
.
 
22
 
 The altered epithelium also becomes an
important source of autacoid mediators, chemokines
and growth factors
 
23
 
 that sustain ongoing inflammation.
To explain the disordered morphology and extent of
activation, we have investigated whether the asthmatic
epithelium is more susceptible to injury and/or has an
altered response to damage.
 
Epithelial susceptibility
 
Epithelial disruption is characteristically increased in the
asthmatic bronchial epithelium. It has been proposed
that this damage is artefactual;
 
24
 
 however, our findings
of enhanced expression of the epidermal growth factor
receptor (EGFR, HER-1, c-erbB1)
 
25
 
 and the epithelial
isoform of CD44
 
26
 
 indicate that injury has occurred
 
in vivo
 
. We have found that EGFR and CD44 expression
in asthma increases with disease severity and is evident
throughout the epithelium, suggesting that damage
is widespread.
 
25,26
 
 Significantly, EGFR overexpression is
insensitive to the action of corticosteroids and is posi-
tively correlated with the thickness of the lamina reticula-
ris,
 
25
 
 linking epithelial injury to underlying remodeling.
The extent of epithelial shedding in asthma is not observed
in other inflammatory diseases, such as chronic obstruc-
tive pulmonary disease (COPD), where the epithelium
becomes multilayered due to squamous metaplasia while
the underlying lamina reticularis remains normal. While
these differences may reflect the quality of inflammation,
airway eosinophilia is observed in the absence of
asthma
 
27
 
 and neutrophils may dominate inflammation in
severe asthma, as in COPD.
 
12
 
We have shown increased epithelial expression of Fas
and Fas ligand in patients who have died with asthma. In
bronchial biopsies, there is markedly increased immuno-
staining of asthmatic columnar (but notably not basal)
 EPITHELIAL–MESENCHYMAL INTERACTIONS IN ASTHMA 47
 
epithelial cells for p85, the caspase-3 cleavage product
of poly (ADP-ribose) polymerase, indicating that epithelial
apoptosis is increased in this disease.
 
28
 
 While such obser-
vational studies are able to identify differences between
asthmatic and normal subjects, they are unable to differ-
entiate whether the changes are a cause or consequence
of inflammation. To address this, we have established
primary cultures using bronchial epithelial cells brushed
from the airways of normal and asthmatic subjects in
order to compare responses under identical conditions
 
in vitro
 
. Although no difference in the rate of proliferation
of these cultures under optimal growth conditions has
been found, when rendered quiescent by growth factor
depletion those from asthmatic airways exhibit a signifi-
cantly greater sensitivity to oxidant-induced apoptosis in
the face of a normal apoptotic response to the DNA and
RNA synthesis inhibitor actinomycin D.
 
28
 
 This suscept-
ibility to oxidants is unlikely to be a secondary effect of
airway inflammation in being preserved through several
generations 
 
in vitro
 
. Because epidemiologic studies
 
27
 
 and
limited investigations in primates
 
29
 
 have identified multiple
interacting risk factors for asthma, including inhalant pol-
lutants and diets low in anti-oxidants, we propose that the
effect of environmental oxidants on a susceptible epi-
thelium provides a plausible triggering mechanism for the
induction of epithelial activation and damage in asthma.
Once initiated, the resulting inflammatory cell influx
causes secondary damage through the production of
endogenous reactive oxygen, resulting in chronic tissue
injury and persistent inflammation. Consistent with this
proposal, we have shown recently that the epithelial
expression of the neutrophil chemoattractants IL-8 and
macrophage inflammatory protein (MIP)-1
 
α
 
 is increased
in severe asthma and that their appearance correlates
with increased EGFR expression as a marker of epithelial
damage. Further 
 
in vitro
 
 studies have revealed that oxidant
or EGF treatment of primary bronchial epithelial cells
enhances MIP-1
 
α
 
 or IL-8 release, respectively.
 
30
 
 Thus, the
susceptibility of the epithelial barrier to the action of differ-
ent components of the inhaled environment may play a
key role in determining the asthmatic phenotype.
 
Growth arrest and epithelial repair
 
Our 
 
in vitro
 
 studies point to a central role for activation
of the EGFR in the restoration of the bronchial epi-
thelium following injury because: (i) EGF is a mitogen
for bronchial epithelial cells;
 
22
 
 (ii) mechanical damage
induces rapid phosphorylation of the EGFR irrespective
of the presence of exogenous ligand;
 
25
 
 and (iii) wound
closure is enhanced by EGF but not by the unrelated
ligand keratinocyte growth factor (KGF, FGF-7).
 
25
 
Recognizing that EGF is a potent mitogen, the increase
in epithelial EGFR in asthma is paradoxical because it
is not matched by increased proliferation to replace
columnar cells that have been shed
 
22,31
 
 and, in this way,
contrasts with the hyperproliferative state of the epi-
thelium seen in COPD. Although studies with primary
cultures of normal and asthmatic bronchial epithelial
cells have shown similar proliferation rates when main-
tained in medium supplemented with exogenous EGF,
 
28
 
we have found a potential mechanism for reduced
EGFR-mediated proliferation 
 
in vivo
 
 because the cyclin-
dependent kinase inhibitor p21
 
waf
 
 is overexpressed in
basal, as well as columnar, epithelial cells in bronchial
biopsies from patients with severe asthma.
 
22
 
 In response
to injury, p21
 
waf
 
 acts as a checkpoint at the G1 to
S-phase transition of the cell cycle, causing growth arrest
to enable DNA repair to be completed before progres-
sion into S-phase or, where damage is irreparable, to
direct exit from the cell cycle and activate apoptosis.
In this way, the decisions to survive or to enter into
apoptosis are irrefutably linked. The EGFR ligands
(EGF, TGF-
 
α
 
, amphiregulin, heparin-binding epidermal
growth factor-like growth factor (HB-EGF), epiregulin
and betacellulin) are pivotal determinants of epithelial
cell fate through their ability to act as survival factors
 
32
 
that protect against pro-apoptotic stimuli and as mitogens
that signal cell cycle progression. Although we have not
yet characterized the ability of EGF to protect against
oxidant-induced apoptosis 
 
in vitro
 
, studies in animal
models have shown that EGF can protect against
smoke-induced tracheal injury in sheep.
 
33
 
Because expression of p21
 
waf
 
 is strongly induced by
oxidant stress,
 
22
 
 our finding
 
28
 
 that asthmatic bronchial
epithelial cells are more susceptible to oxidant injury
provides one explanation for the high expression of
p21
 
waf
 
 in the asthmatic epithelium. However, p21
 
waf
 
 is
also induced by the antiproliferative growth factors
TGF-
 
β
 
1 and TGF-
 
β
 
2, the levels of which are elevated
in asthma, in COPD
 
34
 
 and in response to epithelial injury
 
in vitro
 
.
 
25,35
 
 Because mitogen-activated protein kinase
(MAPK) activation by mitogens such as EGF antagonizes
TGF-
 
β
 
 signaling,
 
36
 
 the overall fate of the epithelium will
reflect integration of survival and proliferation signals
provided by EGF-like growth factors and the counter-
balancing effect pro-apoptotic and antiproliferative
signals caused by injury and members of the TGF-
 
β
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family. Although expression of EGF, TGF-
 
α
 
 and HB-EGF
 
37
 
is unchanged in asthmatic bronchial epithelium relative
to normal controls, our unpublished studies in COPD
indicate markedly increased TGF-
 
α
 
 production. Thus, in
COPD, increased activation of the EGFR by EGF and
analogous ligands protects against cigarette smoke-
induced injury and overrides the antiproliferative effect of
TGF-
 
β
 
, whereas in asthma an insufficiency of these
ligands provides a unifying mechanism for increased epi-
thelial susceptibility and impaired repair. This is sup-
ported by our finding of a marked decrease in epithelial
immunostaining for phosphotyrosine (a global marker of
tyrosine kinase activation) in the bronchial epithelium in
mild asthma
 
38
 
 and the reported lack of MAPK activa-
tion.
 
39
 
 In contrast, in corticosteroid-refractory asthma,
tyrosine kinase activity is markedly increased in relation to
disease severity or treatment.
 
38
 
 Although we have not yet
identified the phosphorylated proteins within the
asthmatic epithelium, they are more likely to be linked
to stress-induced growth arrest than to proliferation
because, in the bronchial epithelium of severe asthmatic
subjects, p21
 
waf
 
 is elevated whereas proliferating cell
nuclear antigen (PCNA) remains low.
 
22
 
In asthma, we have also discovered that there is no
increase in epithelial expression of the structurally related
heregulin receptors HER-2 (c-erbB2) or HER-3 (c-erbB3),
 
37
 
whereas in COPD both these receptors are over-
expressed in parallel with the EGFR (ST Holgate et al.,
unpubl. obs., 2002). As EGFR : EGFR homodimers are
only weak activators of the MAPK pathway,40 this will
further contribute to the inability of the asthmatic epi-
thelium to counter antiproliferative signals provided
by TGF-β. In contrast, EGFR : HER-2 heterodimers are
potent signal transducers41 and will augment epithelial
proliferation in COPD, whereas c-erbB3-containing hetero-
dimers are able to promote cell survival due to the pres-
ence of multiple binding sites for phosphatidylinositol
3-kinase on this receptor.42 Based on these findings, we
hypothesize that the duration of epithelial repair is pro-
longed in asthma due to an imbalance between prolifer-
ation and survival signals involving the EGFR/HER family
and antiproliferative signals involving TGF-β.
THE EPITHELIAL–MESENCHYMAL TROPHIC UNIT
Epithelial–mesenchymal signaling
High-resolution computed tomography, post-mortem and
biopsy studies in chronic asthma have all revealed
airway wall thickening. This involves deposition of inter-
stitial collagens in the lamina reticularis,43 matrix depo-
sition in the submucosa, smooth muscle hyperplasia and
microvascular and neuronal proliferation. Thickening of
the lamina reticularis is diagnostic of this disease and,
on the basis of measurements made in human airways44
and in a guinea pig model of chronic antigen expo-
sure,45,46 it appears to reflect events linked to thickening
of the entire airway wall.47 In 1990, we described a
layer of subepithelial mesenchymal cells with features of
myofibroblasts, the number of which was increased in
asthma in proportion to the thickness of the reticular
collagen layer.48 These cells correspond to the attenu-
ated fibroblast sheath described by Evans et al.49 lying
adjacent to the lamina reticularis and forming a network
similar to hepatic stellate cells which, when activated by
liver damage, are the key effector cells responsible for
fibrosis.50 Because the bronchial epithelium is in intimate
contact with the attenuated fibroblast sheath, these
two cellular layers are in a key position to coordinate
responses to challenges from the inhaled environment
into the deeper layers of the submucosa.51 We have
already demonstrated that injury to epithelial mono-
layers in vitro results in increased release of fibroprolifer-
ative and fibrogenic growth factors including fibroblast
growth factor (FGF)-2, insulin-like growth factor-1 (IGF-1),
platelet-derived growth factor (PDGF), endothelin (ET)-1
and latent and active TGF-β2.35,52 We have also found
that TGF-β, FGF-2 and ET-1 are increased in asthma,53–55
with TGF-β and FGF-2 being encrypted in the extra-
cellular matrix, as shown by their colocalization with the
proteoglycans decorin and heparan sulfate, respec-
tively.56 To further establish the relationship between
EGFR signaling in the repair and remodeling processes,
we have used an EGFR-selective tyrosine kinase inhibitor
that suppresses epithelial repair in vitro with a resultant
increase in release of TGF-β2 by the damaged epithelial
cells.25 This points to parallel pathways operating in
repairing epithelial cells, some of which direct efficient
restitution and are regulated by the EGFR, whereas
others control profibrogenic growth factor production
independent of the EGFR. In asthma, we suggest that
impaired epithelial proliferation causes the bronchial
epithelium to spend longer in a repair phenotype,
resulting in increased secretion of profibrogenic growth
factors.
Using a coculture model, we have obtained direct
evidence that epithelial injury causes myofibroblast
activation. Thus, polyarginine (a surrogate for eosinophil
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basic proteins) or mechanical damage to confluent mono-
layers of bronchial epithelial cells grown on a collagen
gel seeded with human myofibroblasts leads to enhanced
proliferation and increased collagen gene expression
due to the combined effects of FGF-2, IGF-1, PDGF-BB,
TGF-β and ET-1.35 Furthermore, in mild–moderate
asthma, inhaled corticosteroids reduce airway inflamma-
tion and levels of IGF-1 and FGF-2, but with minimal
improvement in BHR and no effect on collagen deposi-
tion in the lamina reticularis or on TGF-β levels.57
Because we have shown that the corticosteroids reduced
submucosal eosinophils by 80%, the persistently high
TGF-β in bronchoalveolar lavage fluid (BALF) most likely
derives from the injured and repairing epithelium and
associated matrix turnover rather than from eosinophils.
Because both epithelial EGFR expression25 and TGF-β
production are refractory to corticosteroids, the com-
bined effects of these signaling pathways on the EMTU
could provide mechanisms for tissue remodeling and
explain the incomplete resolution of lung function with
inhaled corticosteroids observed in chronic asthma.
Communication between the epithelium and the sub-
epithelial fibroblast sheath is reminiscent of the processes
that drive physiological remodeling of the airways during
embryogenesis, where the epithelium and mesenchyme
act as a ‘trophic unit’ to regulate airway growth and
branching.58 Consequently, we propose that the EMTU is
reactivated in asthma to drive pathologic remodeling of
the airways.51 In subjects with asymptomatic BHR, longi-
tudinal studies have shown that those who progress
to asthma show parallel changes in inflammation and
remodeling.59 Thickening of the lamina reticularis in
bronchial biopsies from young children is also present
several years before asthma becomes clinically mani-
fest.16 During lung development, epithelial and mesen-
chymal growth is regulated, in part, by the balance of
EGF and TGF-β signaling, as we suggest occurs in
chronic asthma. In susceptible individuals, we propose
that environmental factors interact with the EMTU in early
life to initiate structural changes in the airways that may
account for the decrease in lung function observed in
young children who are susceptible to early wheezing60
and for the loss of corticosteroid responsiveness on base-
line lung function observed in the CAMP study.14 This is
supported by very recent studies in non-human primates,
where intermittent exposure to ozone in the presence
of allergen creates a phenotype resembling chronic
asthma.29 Therefore, bronchial epithelial susceptibility
seems to either precede or occur in parallel with factors
predisposing to Th-2-mediated inflammation and is an
absolute requirement to establish the microenvironment
for inflammation to become persistent in the airways and
for remodeling to occur.
Propagation of remodeling responses by the 
EMTU
To study the mesenchymal cells that are involved in the
remodeling responses in asthma, we have established
protocols for their outgrowth from bronchial biopsies.
These vimentin-positive fibroblasts can be grown readily
from asthmatic mucosal biopsies and differ from those
from normal airways in adopting stem cell characteris-
tics, by proliferating rapidly in the absence of exogenous
growth factors and by their ability to overcome contact
inhibition in the presence of TGF-β1 or TGF-β2, enab-
ling higher cell densities to be achieved.61 In this regard,
TGF-β treatment in vitro also causes submucosal fibro-
blasts to adopt a myofibroblast phenotype, as evidenced
by induction of α-smooth muscle actin (SMA), acquisition
of a contractile phenotype and synthesis of interstitial
(repair) collagens. Although the relationship between
myofibroblast activation and the underlying smooth
muscle mass in asthma has yet to be studied, following
allergen exposure we have found an increase in BALF of
the smooth muscle and vascular mitogen, ET-155 and
that TGF-β treatment of asthmatic mucosal fibroblasts
in vitro causes them to release both ET-1 and another
vascular mitogen, namely vascular endothelial growth
factor (VEGF).61 Thus, in addition to increased matrix
deposition, activation of myofibroblasts contributes to
smooth muscle and microvascular proliferation, which
are both characteristic features of the remodeled asth-
matic airway.62
In a rabbit model of partial outflow obstruction in the
bladder, TGF-β causes serosal thickening due to accum-
ulation of myofibroblasts, which, over time, change
phenotype into smooth muscle cells.63 In developing cap-
illaries, endothelial cells and smooth muscle cells also
share a common stem cell progenitor with VEGF and
PDGF acting as the key determinants of cell fate.64 Our
own studies of normal and asthmatic airway (myo) fibro-
blasts reveal that these cells exhibit phenotypic plasticity,
have some early features of smooth muscle (e.g. expres-
sion of the SM-22 protein) and can be further differenti-
ated by TGF-β1 and TGF-β2 to express heavy chain
myosin (HCM) and α-SMA.61,65 This suggests that the
cells have properties of both myofibroblasts and smooth
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muscle cells and are probably derived from a common
(? stem cell) progenitor. Thus, mediators released by the
repairing bronchial epithelium provide a mechanism for
myofibroblast activation to propagate and amplify airway
remodeling. Such a mechanism would fit well with the
recent findings on airway smooth muscle cultured from
asthmatic airways.62
INTERACTION BETWEEN IL-4 AND IL-13 AND 
THE EMTU
Th-2 type inflammation of the airways is a characteristic
feature of asthma, irrespective of atopy. In view of
transgenic mice studies that have suggested that expres-
sion of an IL-13 (but not IL-4) transgene in the bronchial
epithelium leads to submucosal remodeling,66,67 we
have investigated the role of IL-4 and IL-13 in asthmatic
epithelial cell and fibroblast function. The expression of
the high-affinity IL-13Rα2 chain is restricted to airway
epithelial cells and fibroblasts and is coexpressed with
IL-13Rα1 and IL-4Rα.68 Both IL-4 and IL-13 signal via
the transcription factor STAT-6,69 the expression of which
we have shown to be prominent in the bronchial
epithelium and further increased in severe asthma.70
While we have shown that IL-13 is able to induce
myofibroblast transformation, it is two orders of magni-
tude less potent than TGF-β and is equipotent with IL-4
in this effect.61 Because parallel experiments revealed
that IL-13 causes a corticosteroid-insensitive increase
in release of TGF-β2 from bronchial epithelial cells, it
seems likely that IL-13-mediated submucosal remode-
ling is initiated largely through the bronchial epi-
thelium.61 A recent report from Lee et al.70 supports this
conclusion because both fibrosis and smooth muscle
hyperplasia in the airways of mice expressing a bron-
chial epithelial-specific IL-13 transgene are TGF-β
dependent. However, in human epithelial cells, IL-4 is as
effective as IL-13 in promoting TGF-β release,71 raising
the possibility of an important species difference in
epithelial IL-4 and IL-13 receptor expression.
While the remodeling effects of IL-4 and IL-13 can be
attributed to epithelial activation, these cytokines also
have direct pro-inflammatory effects on both epithelial
cells and fibroblasts. Cultures of bronchial epithelial
cells respond to IL-4 and IL-13 with increased STAT-6
phosphorylation accompanied by enhanced granulocyte–
macrophage colony stimulating factor and IL-8 pro-
duction, which is further augmented by enzymatically
active extracts of house dust mite (Dermatophagoides
pteronyssinus).71,72 We have also found enhanced release
of eotaxin from asthmatic fibroblasts61 that may help
explain the accumulation of eosinophils beneath the
lamina reticularis in asthma. Thus, by interacting with
the EMTU, IL-4 and IL-13 contribute to chronic inflam-
mation and airway remodeling.
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